Skip to content

The effect of smoking on the dose-effect relationship of ciprofol compound alfentanil for painless gastroscopy

The effect of smoking on the dose-effect relationship of ciprofol compound alfentanil for painless gastroscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079337
Enrollment
Unknown
Registered
2024-01-01
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless gastroscopy

Interventions

Smoking group:The Dixon sequential method was used, and the initial dose of ciprofol was set to 0.4 mg/kg and the dose gradient was 0.04 mg/kg. Body movement, choking, swallowing and other reactions w
Otherwise, the next patient decreases 0.04 mg/kg. If the Modified Observer's Assessment of Alertness/Sedation Scale(MOAA/S scale) is still> 1 point 3 min after injection of ciprofol, sedation is dire
No smoking group:The Dixon sequential method was used, and the initial dose of ciprofol was set to 0.4 mg/kg and the dose gradient was 0.04 mg/kg. Body movement, choking, swallowing and other reaction

Sponsors

Baoding NO.1 Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Male patients to undergo elective painless gastroscopy; 2, age <65 years; 3, BMI <28 kg/m2; 4, ASA grade ? or ?; 5, mouth opening = 2.5 cm; 6, normal head and neck mobility; 7, Mallampati grade ? or ? ; 8, the patient had fully understood the nature of the study, volunteered to participate in the trial and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. History of allergy to test drugs; 2. History of neurological diseases; 3. High risk of inhalation; 4. Expected airway difficulty; 5. Long-term use of sedatives; 7. Acute upper gastrointestinal bleeding; 8. Any condition considered to be unsuitable for any reason

Design outcomes

Primary

MeasureTime frame
median effective dose;

Secondary

MeasureTime frame
Adverse effects such as bradycardia, hypotension, hypoxia, choking, body movement, and swallowing during the induction period;SpO2, HR and MAP were recorded before anesthesia (T0), 1min after injection (T1) and gastroscopy (T2);

Countries

China

Contacts

Public ContactChunguang Wang

Baoding NO.1 Central Hospital

13831253611@163.com+86 186 1778 9771

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026